Developer docs
API playgroundTry for free, no card

Search company profiles

Oncodesign Services

Full company profile

uuid0002l1m

Namestring
Oncodesign Services
Legal namestring
Oncodesign Services
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Oncodesign Services is a private contract research organization (CRO) headquartered in Dijon, France, specializing in preclinical drug discovery and translational pharmacology, primarily for oncology and inflammation. Founded in 1995/1996, the company operates approximately 280 employees across four countries (France, the Netherlands, the United States, and Canada) and reported €44 million in revenue following its January 2024 acquisition of Dutch biophysics CRO ZoBio, funded by a €22 million minority investment from Eurazeo's Nov Santé Actions Non Cotées fund.

The company's core technology stack spans the full preclinical workflow: structural biology (SPR, NMR, TINS, cryo-EM via ZoBio), medicinal chemistry (small molecules, PROTACs, fragments), in vitro biology, DMPK, bioanalysis, bioconjugation/radiochemistry for molecular radiotherapy (MRT), in vivo pharmacology, and pharmaco-imaging. Its proprietary in-house portfolio of more than 500 characterized tumor models (PDX, CDX, syngeneic) across 20 organ origins, together with humanized mouse models for immuno-oncology and GLP-compliant facilities with AAALAC International accreditation, constitutes a deeply specialized translational research engine. Service offerings are packaged into integrated branded solutions—EXPLORE (target ID/validation), DRIVE-IDDS (hit-to-lead across modalities), INPACT (preclinical pharmacology), SOLO (technical platform access), and D-VLOP (IND-enabling work)—alongside discrete therapeutic area services in oncology, inflammation, microbiome, and infectious disease (BSL2/BSL3).

Revenue is generated through project-based, long-term professional services contracts with pharmaceutical and biotechnology companies, delivered via direct enterprise field sales with dedicated project leaders as single points of contact. Pricing is not publicly disclosed and is quote-based per project scope. Customer segments are primarily large pharma and biotech companies (with academic/research institutions as a secondary segment), and go-to-market emphasizes scientific expertise and integrated workflow selling. Recent strategic moves signal a deliberate pivot into radiopharmaceuticals (Debiopharm and GIP ARRONAX collaborations) and continued internationalization, while consecutive "Oncology CRO of the Year – France" awards in 2024 and 2025 reflect brand strength in translational oncology.

Short descriptiontext

Oncodesign Services is a private French CRO providing integrated preclinical drug discovery and translational pharmacology services—spanning biophysics, medicinal chemistry, in vivo pharmacology, tumor models, and radiopharmaceuticals—to pharmaceutical and biotechnology companies across Europe and North America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDijon, France
HQ citystring
Dijon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical drug discovery, contract research services, oncology translational pharmacology, radiopharmaceutical development, in vivo pharmacology services
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Preclinical Contract Research Services (Drug Discovery CRO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Oncodesign Services generates revenue through providing contract research organization (CRO) services for drug discovery and preclinical development. Services span target identification, hit-to-lead, lead optimization, in vitro/in vivo pharmacology, bioanalysis, DMPK, and regulatory filing support (IND). Revenue is project-based, typically long-term contracts with pharmaceutical and biotechnology companies.

oncodesign-services.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Oncodesign Services is a contract research organization (CRO) that provides integrated preclinical drug discovery services for pharmaceutical and biotechnology clients. Its offerings span target identification and validation, medicinal chemistry, in vitro and in vivo pharmacology, DMPK, bioanalysis, bioconjugation/radiochemistry, and IND-enabling work, with oncology, inflammation, infectious disease, and microbiome as primary therapeutic areas. Deliverables are delivered as customized research programs through dedicated project leaders from laboratories in France, the Netherlands, Canada, and the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully developed several drug candidates that have reached clinical development phase together with partner clients
+1 more record
Product overview1 text field

Oncodesign Services is a Contract Research Organization (CRO) specializing in drug discovery and preclinical services, offering integrated solutions from target identification to IND filing. The portfolio includes Discovery Services (Structural Biology, Medicinal Chemistry, In Vitro Biology, DMPK, Bioanalysis, Bioconjugation/Radiochemistry, In Vivo Pharmacology, and Pharmaco-Imaging), Integrated Solutions (EXPLORE for target ID/validation, DRIVE-IDDS for integrated drug discovery, INPACT for preclinical pharmacology, SOLO for technical platforms, and D-VLOP for IND filing), and specialized therapeutic area services in Oncology (Tumor Models, PDX, CDX, Humanized Models, Immuno-Oncology, MRT) and Inflammation (IBD, Dermal, Endometriosis, Autoimmunity, GvHD, CNS, and other organ-specific models). The company also provides Microbiome and Infectious Disease services, with ZoBio providing biophysics capabilities following its 2024 acquisition.

Product and service31 records
1EXPLORE (Target Identification and Validation)
CategoryIntegrated Drug Discovery Solution
2DRIVE-IDDS (Integrated Drug Discovery Solution)
CategoryIntegrated Drug Discovery Solution
3INPACT (Preclinical Pharmacology Integrated Services)
CategoryIntegrated Drug Discovery Solution
4SOLO (Innovative Technical Platforms)
CategoryIntegrated Drug Discovery Solution
5D-VLOP (Drug to IND Filing)
CategoryIntegrated Drug Discovery Solution
6Structural Biology Services
CategoryDiscovery Service
7Medicinal Chemistry
CategoryDiscovery Service
8In Vitro Biology
CategoryDiscovery Service
9DMPK (Drug Metabolism and Pharmacokinetics)
CategoryDiscovery Service
10Bioanalysis, Formulation, Immunogenicity and Biomarkers
CategoryDiscovery Service
11Bioconjugation and Radiochemistry Platform
CategoryDiscovery Service
12In Vivo Pharmacology
CategoryDiscovery Service
13Pharmaco-Imaging (In Vivo Imaging)
CategoryDiscovery Service
14Oncology Immuno-Oncology Services
CategoryTherapeutic Area Service
15Oncology Tumor Models
CategoryOncology Service
16Orthotopic Tumor Models
CategoryOncology Service
17Metastatic Tumor Models
CategoryOncology Service
18Humanized Mouse Models
CategoryOncology Service
19Radiopharmaceutical Development (MRT)
CategoryOncology Service
20Autoimmunity Models
CategoryInflammation Service
21Dermal Inflammation Models
CategoryInflammation Service
22Endometriosis Models
CategoryInflammation Service
23IBD Models
CategoryInflammation Service
24Kidney Inflammation Models
CategoryInflammation Service
25Liver Inflammation Models
CategoryInflammation Service
26Lung Inflammation Models
CategoryInflammation Service
27Systemic Inflammation Models
CategoryInflammation Service
28CNS Inflammation Models
CategoryInflammation Service
29Microbiome Services
CategorySpecialized Service
30ZoBio Biophysics Platform
CategoryAcquired Service (Biophysics)
31Infectious Disease Preclinical Services
CategorySpecialized Service
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2026-04-13
Description

Extended collaboration with GIP ARRONAX to strengthen access to astatine-211 (At-211) supply for targeted alpha radiotherapy programs. GIP ARRONAX provides access to this critical radioisotope used in molecular radiotherapy development.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Strategic collaboration between Debiopharm and Oncodesign Services to advance radiopharmaceuticals in preclinical research. The partnership focuses on leveraging Oncodesign Services' molecular radiotherapy platform and expertise in radiopharmaceutical development.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Oncodesign Services participated in the Medicen 'Microbiome Drug Metabolism' working group, led by Patrick Jimonet. Sylvie Maubant from Oncodesign Services co-led the 'In vivo' working group. The collaboration produced a comprehensive review published in Drug Metabolism and Disposition journal, with over 30 international experts contributing proposals for integrating microbiome considerations in drug discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

ZoBio, a boutique CRO based in Leiden, Netherlands specializing in biophysics-based drug discovery, was acquired by Oncodesign Services in 2024. ZoBio brings capabilities including biophysical and functional assays, protein production, structural biology (crystallography, NMR, cryo-EM), and fragment-focused medicinal chemistry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty discovery CRO offering biophysics, biochemistry, and in vitro pharmacology services to pharma and biotech. Comparable to Oncodesign through its biophysics capabilities acquired with ZoBio, with overlap in SPR, NMR-based assay development.

2HD Biosciences
TypeDirect peer
Description

Mid-sized preclinical CRO offering in vitro and in vivo pharmacology, immuno-oncology, and disease models. Comparable to Oncodesign in therapeutic-area focus, integrated preclinical offerings, and client base of pharma/biotech sponsors.

TypeBroad incumbent
Description

Integrated drug discovery CRO offering target ID through preclinical services, including partnerships in oncology and radiopharmaceuticals. Comparable to Oncodesign in providing integrated discovery platforms, though broader in scope and modality coverage.

TypeBroad incumbent
Description

Discovery services arm of Eurofins Scientific offering medicinal chemistry, in vitro pharmacology, ADME, and in vivo services. Comparable to Oncodesign in integrated preclinical offerings with broader test menu and larger scale across multiple geographies.

TypeBroad incumbent
Description

Global CRO/CDMO offering discovery, preclinical, and clinical services with very large scale. Comparable to Oncodesign across preclinical pharmacology, DMPK, and bioanalysis, with much broader geographic reach and integrated development services.

TypeBroad incumbent
Description

Full-service CRO providing drug discovery, DMPK, bioanalysis, and in vivo pharmacology across multiple therapeutic areas. Overlaps with Oncodesign across integrated discovery, bioanalysis, and preclinical model capabilities, with a broader China-rooted footprint.

7Bienta (Enamine)
TypeRegional player
Description

Preclinical CRO based in Ukraine/Europe offering integrated drug discovery, in vivo pharmacology, and bioanalysis services. Comparable to Oncodesign in integrated preclinical offerings and European pharma/biotech customer base, though with a different geographic footprint.

TypeBroad incumbent
Description

Biotechnology services provider offering biologics discovery, cell therapy, and preclinical services including tumor models and bioanalysis. Comparable to Oncodesign across biologics discovery, bioanalysis, and oncology in vivo services with broader CDMO exposure.

TypeBroad incumbent
Description

Global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple therapeutic areas. Overlaps with Oncodesign in preclinical in vivo pharmacology, oncology models, and DMPK/bioanalysis but operates at materially larger scale.

TypeDirect peer
Description

Specialty preclinical oncology CRO with extensive PDX, CDX and humanized mouse model portfolios serving pharma and biotech sponsors. Closely comparable to Oncodesign on therapeutic-area focus (oncology), in vivo pharmacology capabilities, and translational model depth.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncodesign Services

Preclinical Contract Research Services (Drug Discovery CRO)oncodesign-services.com

Oncodesign Services is a private French CRO providing integrated preclinical drug discovery and translational pharmacology services—spanning biophysics, medicinal chemistry, in vivo pharmacology, tumor models, and radiopharmaceuticals—to pharmaceutical and biotechnology companies across Europe and North America.

What Oncodesign Services does

Oncodesign Services is a private contract research organization (CRO) headquartered in Dijon, France, specializing in preclinical drug discovery and translational pharmacology, primarily for oncology and inflammation. Founded in 1995/1996, the company operates approximately 280 employees across four countries (France, the Netherlands, the United States, and Canada) and reported €44 million in revenue following its January 2024 acquisition of Dutch biophysics CRO ZoBio, funded by a €22 million minority investment from Eurazeo's Nov Santé Actions Non Cotées fund.

The company's core technology stack spans the full preclinical workflow: structural biology (SPR, NMR, TINS, cryo-EM via ZoBio), medicinal chemistry (small molecules, PROTACs, fragments), in vitro biology, DMPK, bioanalysis, bioconjugation/radiochemistry for molecular radiotherapy (MRT), in vivo pharmacology, and pharmaco-imaging. Its proprietary in-house portfolio of more than 500 characterized tumor models (PDX, CDX, syngeneic) across 20 organ origins, together with humanized mouse models for immuno-oncology and GLP-compliant facilities with AAALAC International accreditation, constitutes a deeply specialized translational research engine. Service offerings are packaged into integrated branded solutions—EXPLORE (target ID/validation), DRIVE-IDDS (hit-to-lead across modalities), INPACT (preclinical pharmacology), SOLO (technical platform access), and D-VLOP (IND-enabling work)—alongside discrete therapeutic area services in oncology, inflammation, microbiome, and infectious disease (BSL2/BSL3).

Revenue is generated through project-based, long-term professional services contracts with pharmaceutical and biotechnology companies, delivered via direct enterprise field sales with dedicated project leaders as single points of contact. Pricing is not publicly disclosed and is quote-based per project scope. Customer segments are primarily large pharma and biotech companies (with academic/research institutions as a secondary segment), and go-to-market emphasizes scientific expertise and integrated workflow selling. Recent strategic moves signal a deliberate pivot into radiopharmaceuticals (Debiopharm and GIP ARRONAX collaborations) and continued internationalization, while consecutive "Oncology CRO of the Year – France" awards in 2024 and 2025 reflect brand strength in translational oncology.

Oncodesign Services firmographics

Firmographics
Name
Oncodesign Services
Legal name
Oncodesign Services
Website
https://oncodesign-services.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
101–250 employees
Short description
Oncodesign Services is a private French CRO providing integrated preclinical drug discovery and translational pharmacology services—spanning biophysics, medicinal chemistry, in vivo pharmacology, tumor models, and radiopharmaceuticals—to pharmaceutical and biotechnology companies across Europe and North America.
Ownership category
akta.pro rank

Oncodesign Services industry classification

Industry
Product category
Preclinical Contract Research Services (Drug Discovery CRO)
NAICS
Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Preclinical drug discovery
  • Contract research services
  • Oncology translational pharmacology
  • Radiopharmaceutical development
  • In vivo pharmacology services

Where Oncodesign Services is headquartered

Location

Headquarters

HQ city
Dijon
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Oncodesign Services business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Oncodesign Services generates revenue through providing contract research organization (CRO) services for drug discovery and preclinical development. Services span target identification, hit-to-lead, lead optimization, in vitro/in vivo pharmacology, bioanalysis, DMPK, and regulatory filing support (IND). Revenue is project-based, typically long-term contracts with pharmaceutical and biotechnology companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Oncodesign Services product offering

Product offering

Core offering

Oncodesign Services is a contract research organization (CRO) that provides integrated preclinical drug discovery services for pharmaceutical and biotechnology clients. Its offerings span target identification and validation, medicinal chemistry, in vitro and in vivo pharmacology, DMPK, bioanalysis, bioconjugation/radiochemistry, and IND-enabling work, with oncology, inflammation, infectious disease, and microbiome as primary therapeutic areas. Deliverables are delivered as customized research programs through dedicated project leaders from laboratories in France, the Netherlands, Canada, and the United States.

Product overview

Oncodesign Services is a Contract Research Organization (CRO) specializing in drug discovery and preclinical services, offering integrated solutions from target identification to IND filing. The portfolio includes Discovery Services (Structural Biology, Medicinal Chemistry, In Vitro Biology, DMPK, Bioanalysis, Bioconjugation/Radiochemistry, In Vivo Pharmacology, and Pharmaco-Imaging), Integrated Solutions (EXPLORE for target ID/validation, DRIVE-IDDS for integrated drug discovery, INPACT for preclinical pharmacology, SOLO for technical platforms, and D-VLOP for IND filing), and specialized therapeutic area services in Oncology (Tumor Models, PDX, CDX, Humanized Models, Immuno-Oncology, MRT) and Inflammation (IBD, Dermal, Endometriosis, Autoimmunity, GvHD, CNS, and other organ-specific models). The company also provides Microbiome and Infectious Disease services, with ZoBio providing biophysics capabilities following its 2024 acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

  • EXPLORE (Target Identification and Validation)
  • DRIVE-IDDS (Integrated Drug Discovery Solution)
  • INPACT (Preclinical Pharmacology Integrated Services)
  • SOLO (Innovative Technical Platforms)
  • D-VLOP (Drug to IND Filing)
  • Structural Biology Services
  • Medicinal Chemistry
  • In Vitro Biology
  • DMPK (Drug Metabolism and Pharmacokinetics)
  • Bioanalysis, Formulation, Immunogenicity and Biomarkers
  • Bioconjugation and Radiochemistry Platform
  • In Vivo Pharmacology
  • Pharmaco-Imaging (In Vivo Imaging)
  • Oncology Immuno-Oncology Services
  • Oncology Tumor Models
  • Orthotopic Tumor Models
  • Metastatic Tumor Models
  • Humanized Mouse Models
  • Radiopharmaceutical Development (MRT)
  • Autoimmunity Models
  • Dermal Inflammation Models
  • Endometriosis Models
  • IBD Models
  • Kidney Inflammation Models
  • Liver Inflammation Models
  • Lung Inflammation Models
  • Systemic Inflammation Models
  • CNS Inflammation Models
  • Microbiome Services
  • ZoBio Biophysics Platform
  • Infectious Disease Preclinical Services

Quantifiable outcome

  • Successfully developed several drug candidates that have reached clinical development phase together with partner clients
  • +1 more outcomes

Companies that use Oncodesign Services

Customer profile

Segments3 records

Ideal customer profiles3 records

Oncodesign Services technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Oncodesign Services partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered important, major, supporting and core.

  • GIP ARRONAXimportantStrategic or Co-development Partner · 13 April 2026Extended collaboration with GIP ARRONAX to strengthen access to astatine-211 (At-211) supply for targeted alpha radiotherapy programs. GIP ARRONAX provides access to this critical radioisotope used in molecular radiotherapy development.
  • DebiopharmmajorStrategic or Co-development Partner · 24 April 2025Strategic collaboration between Debiopharm and Oncodesign Services to advance radiopharmaceuticals in preclinical research. The partnership focuses on leveraging Oncodesign Services' molecular radiotherapy platform and expertise in radiopharmaceutical development.
  • Medicen Paris RegionsupportingStrategic or Co-development Partner · 1 February 2024Oncodesign Services participated in the Medicen 'Microbiome Drug Metabolism' working group, led by Patrick Jimonet. Sylvie Maubant from Oncodesign Services co-led the 'In vivo' working group. The collaboration produced a comprehensive review published in Drug Metabolism and Disposition journal, with over 30 international experts contributing proposals for integrating microbiome considerations in drug discovery.
  • ZoBiocoreStrategic or Co-development Partner · 1 January 2024ZoBio, a boutique CRO based in Leiden, Netherlands specializing in biophysics-based drug discovery, was acquired by Oncodesign Services in 2024. ZoBio brings capabilities including biophysical and functional assays, protein production, structural biology (crystallography, NMR, cryo-EM), and fragment-focused medicinal chemistry.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Oncodesign Services competitors and assessment

Company assessment

Direct peers

  • Reaction Biology: Specialty discovery CRO offering biophysics, biochemistry, and in vitro pharmacology services to pharma and biotech. Comparable to Oncodesign through its biophysics capabilities acquired with ZoBio, with overlap in SPR, NMR-based assay development.
  • HD Biosciences: Mid-sized preclinical CRO offering in vitro and in vivo pharmacology, immuno-oncology, and disease models. Comparable to Oncodesign in therapeutic-area focus, integrated preclinical offerings, and client base of pharma/biotech sponsors.
  • Crown Bioscience: Specialty preclinical oncology CRO with extensive PDX, CDX and humanized mouse model portfolios serving pharma and biotech sponsors. Closely comparable to Oncodesign on therapeutic-area focus (oncology), in vivo pharmacology capabilities, and translational model depth.

Broad incumbents

  • Evotec: Integrated drug discovery CRO offering target ID through preclinical services, including partnerships in oncology and radiopharmaceuticals. Comparable to Oncodesign in providing integrated discovery platforms, though broader in scope and modality coverage.
  • Eurofins Discovery: Discovery services arm of Eurofins Scientific offering medicinal chemistry, in vitro pharmacology, ADME, and in vivo services. Comparable to Oncodesign in integrated preclinical offerings with broader test menu and larger scale across multiple geographies.
  • WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and clinical services with very large scale. Comparable to Oncodesign across preclinical pharmacology, DMPK, and bioanalysis, with much broader geographic reach and integrated development services.
  • Pharmaron: Full-service CRO providing drug discovery, DMPK, bioanalysis, and in vivo pharmacology across multiple therapeutic areas. Overlaps with Oncodesign across integrated discovery, bioanalysis, and preclinical model capabilities, with a broader China-rooted footprint.
  • GenScript ProBio: Biotechnology services provider offering biologics discovery, cell therapy, and preclinical services including tumor models and bioanalysis. Comparable to Oncodesign across biologics discovery, bioanalysis, and oncology in vivo services with broader CDMO exposure.
  • Charles River Laboratories: Global preclinical CRO offering discovery, safety assessment, and manufacturing services across multiple therapeutic areas. Overlaps with Oncodesign in preclinical in vivo pharmacology, oncology models, and DMPK/bioanalysis but operates at materially larger scale.

Regional players

  • Bienta (Enamine): Preclinical CRO based in Ukraine/Europe offering integrated drug discovery, in vivo pharmacology, and bioanalysis services. Comparable to Oncodesign in integrated preclinical offerings and European pharma/biotech customer base, though with a different geographic footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Oncodesign Services social profiles

Digital presence

Oncodesign Services compliance and trust

Trust signal

Compliance8 records

Oncodesign Services financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncodesign Services leadership team

Management profile

Number of profiles

Oncodesign Services subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Oncodesign Services funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncodesign Services M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncodesign Services

What does Oncodesign Services do?

Oncodesign Services is a contract research organization (CRO) that provides integrated preclinical drug discovery services for pharmaceutical and biotechnology clients. Its offerings span target identification and validation, medicinal chemistry, in vitro and in vivo pharmacology, DMPK, bioanalysis, bioconjugation/radiochemistry, and IND-enabling work, with oncology, inflammation, infectious disease, and microbiome as primary therapeutic areas. Deliverables are delivered as customized research programs through dedicated project leaders from laboratories in France, the Netherlands, Canada, and the United States.

Is Oncodesign Services a public or private company?

Oncodesign Services is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncodesign Services founded?

Oncodesign Services was founded in 1996. It employs 101 to 250 people.

Where is Oncodesign Services based?

Oncodesign Services is headquartered in Dijon, France, in the Europe region.

How does Oncodesign Services make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Oncodesign Services's main competitors?

Direct peers on record are Reaction Biology, HD Biosciences and Crown Bioscience. Broad incumbents are Evotec, Eurofins Discovery, WuXi AppTec, Pharmaron, GenScript ProBio and Charles River Laboratories. Bienta (Enamine) is listed as a regional player.

Does Oncodesign Services have an API?

No public API is recorded for Oncodesign Services.

What industry is Oncodesign Services in?

Oncodesign Services's product category is Preclinical Contract Research Services (Drug Discovery CRO). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogDebiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical ResearchDebiopharm and Oncodesign Services announced a strategic collaboration to advance radiopharmaceuticals in preclinical research. The article primarily focuses on their partnership efforts without discussing broader strategic implications.PharmiWeb.comOncodesign Services appoints Aidan Synnott as CEO to enhance strategic drug discovery partnershipsOncodesign Services appointed Dr. Aidan Synnott as CEO to strengthen drug discovery partnerships. He brings over 20 years of biomedical research experience, including a role at Charles River Laboratories. He will oversee operations across France and the Netherlands, with Dr. Werner Lanthaler as chairman.PR NewswireOncodesign Services, a Leading European CRO In Preclinical Drug Discovery Acquires ZoBio, A CRO Specialized in Small Molecule Drug DiscoveryOncodesign Services acquired ZoBio, a Dutch CRO specializing in small molecule drug discovery, to expand its preclinical capabilities. The combined entity has nearly 280 employees across France, the Netherlands, Canada, and the US. The deal aims to make ODS a European leader in drug discovery with integrated services.PR NewswireOncodesign Services, a Leading European CRO In Preclinical Drug Discovery Acquires ZoBio, A CRO Specialized in Small Molecule Drug DiscoveryOncodesign Services acquired ZoBio, a Dutch CRO specializing in small molecule drug discovery, to expand its preclinical capabilities. The combined company has nearly 280 employees across France, the Netherlands, Canada, and the US. The deal aims to make ODS a European leader in drug discovery with integrated services.EurazeoTHE NOV SANTÉ ACTIONS NON COTÉES FUND INVESTS IN ONCODESIGN SERVICESThe Nov Santé Actions Non Cotées fund has invested €22 million to acquire a minority stake in Oncodesign Services, which will use the funds to purchase Dutch company ZoBio. This acquisition marks Oncodesign Services' first since its inception and aims to enhance its pre-clinical research services and accelerate its international growth.Funds MagazineEurazeo : Nov Santé Actions Non Cotées investit dans Oncodesign ServicesEurazeo's Nov Santé Actions Non Cotées fund has acquired a minority stake worth 22 million euros in Oncodesign Services, alongside ERES IV SLP and the company's management. This investment finances Oncodesign Services' acquisition of Dutch preclinical research firm ZoBio, expanding its revenue to 44 million euros and workforce to nearly 280 employees. The transaction marks Oncodesign Services' first transformative acquisition since its founding, aiming to establish it as a comprehensive pre-clinical research services provider.Oncodesign-ServicesComputational ChemistryComputational chemistry is used in drug discovery to screen compounds and accelerate timelines, with approaches like ligand-based and structure-based design. Oncodesign Services offers computational chemistry services, including de novo design and lead optimization, and has delivered over 20 preclinical candidates in recent years.Oncodesign-ServicesTarget identificationThe article outlines the necessity of target identification and validation during the preclinical stages of drug discovery to establish molecule efficacy. Oncodesign Services, a Contract Research Organization, offers assistance in this process to ensure project success.News-MedicalOncodesign Services looks to the futureOncodesign Services, spun off from Oncodesign, is led by CEO Fabrice Viviani, who set a €100m sales target in five years. The company, with €30-35m in sales, plans organic growth and acquisitions in North America and Europe, aiming for 70% of sales from integrated services in three years.